Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
Mieczysław Dutka, Rafał Bobiński, Tomasz Francuz, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5811-5811
Open Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

Applications of SGLT2 inhibitors beyond glycaemic control
Daniel V. O’Hara, Carolyn S.P. Lam, John J.V. McMurray, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 8, pp. 513-529
Closed Access | Times Cited: 26
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors
Mohamed S. Dabour, Mina Y. George, Mary R. Daniel, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 2, pp. 159-182
Open Access | Times Cited: 20
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
Nabil V. Sayour, Ágnes Paál, Pietro Ameri, et al.
European Heart Journal (2024) Vol. 45, Iss. 14, pp. 1224-1240
Open Access | Times Cited: 19
New users of sodium-glucose cotransporter 2 inhibitors are at low risk of incident pancreatic cancer: a nationwide population-based cohort study
Yun Kyung Cho, Sehee Kim, Myeong‐Jin Kim, et al.
Diabetes & Metabolism (2025), pp. 101605-101605
Closed Access | Times Cited: 2
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
Mahmoud E. Youssef, Galal Yahya, Mihaela Simona Popoviciu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6039-6039
Open Access | Times Cited: 40
DOXORUBICIN-RELATED CARDIOTOXICITY: REVIEW OF FUNDAMENTAL PATHWAYS OF CARDIOVASCULAR SYSTEM INJURY
Ashot Avagimyan, Nana Pogosova, L. V. Kakturskiy, et al.
Cardiovascular Pathology (2024) Vol. 73, pp. 107683-107683
Closed Access | Times Cited: 13
Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition
Sha Chen, Kenneth Overberg, Zakiya Ghouse, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116477-116477
Open Access | Times Cited: 9
Atherosclerosis and the Bidirectional Relationship Between Cancer and Cardiovascular Disease: From Bench to Bedside, Part 2 Management
Giuseppina Gallucci, Mario Larocca, Alessandro Navazio, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 334-334
Open Access | Times Cited: 1
Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics
Bingbing Li, Cheng Zhang, Xiao-juan Xu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Obesity-induced changes in cancer cells and their microenvironment: Mechanisms and therapeutic perspectives to manage dysregulated lipid metabolism
Miriam Lee‐Rueckert, Marina Canyelles, Mireia Tondo, et al.
Seminars in Cancer Biology (2023) Vol. 93, pp. 36-51
Open Access | Times Cited: 19
Repurposing drugs targeting metabolic diseases for cancer therapeutics
Jisha Pillai U, Anindita Ray, Meenu Maan, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 9, pp. 103684-103684
Closed Access | Times Cited: 18
Comparison between sodium‐glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real‐world evidence study
Hui‐Lin Sung, Chuan‐Yu Hung, Yu‐Chun Tung, et al.
Diabetes/Metabolism Research and Reviews (2024) Vol. 40, Iss. 3
Closed Access | Times Cited: 8
Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity
Vincenzo Quagliariello, Maria Laura Canale, Isabella Bisceglia, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 8
Exploring the therapeutic potential of SGLT2 inhibitors in cancer treatment: integrating in silico and in vitro investigations
Prasanna Mohite, Deepak K. Lokwani, Nikhil S. Sakle
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 8, pp. 6107-6119
Closed Access | Times Cited: 7
Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond
Massimiliano Camilli, Marcello Viscovo, Luca Maggio, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 7
Repurposing metabolic regulators: antidiabetic drugs as anticancer agents
Yogita Dhas, Nupur Biswas, M R Divyalakshmi, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 6
Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease
Xianhua Mao, Xinrong Zhang, Leslie Y. Kam, et al.
Gut (2024) Vol. 73, Iss. 12, pp. 2054-2061
Closed Access | Times Cited: 5
The effect of SGLT2 inhibition on prostate cancer: Mendelian randomization and observational analysis using electronic healthcare and cohort data
Jie Zheng, Jieli Lu, Jiying Qi, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 8, pp. 101688-101688
Open Access | Times Cited: 5
Association of SGLT2 Inhibitors with Incident Cancer
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, et al.
Diabetes & Metabolism (2024) Vol. 50, Iss. 6, pp. 101585-101585
Closed Access | Times Cited: 5
Cancer and Cardiovascular Disease: The Conjoined Twins
Mohammad Zmaili, Jafar Alzubi, Motasem Alkhayyat, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1450-1450
Open Access | Times Cited: 4
Early-Onset Gastrointestinal Cancers and Metabolic Risk Factors: Global Trends From the Global Burden of Disease Study 2021
Pojsakorn Danpanichkul, Kanokphong Suparan, Thanida Auttapracha, et al.
Mayo Clinic Proceedings (2025)
Closed Access
Targeting obesity, metabolic syndrome, and prostate cancer: GLP-1 agonists as emerging therapeutic agents
Azura Murphy, Ritis Kumar Shyanti, Manoj Kumar Mishra
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
The Influence of Performance Status, Inflammation, and Nutrition on the Impact of SGLT2 Inhibitors on Cancer Outcomes
Diego Rivas‐Otero, Tomás González‐Vidal, Pablo Agüeria‐Cabal, et al.
Cancer Medicine (2025) Vol. 14, Iss. 6
Open Access
Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions
Rosaria Maddalena Ruggeri, Erika Grossrubatscher, Eleonora Ciocca, et al.
Reviews in Endocrine and Metabolic Disorders (2025)
Open Access
Not Just an Alternative Energy Source: Diverse Biological Functions of Ketone Bodies and Relevance of HMGCS2 to Health and Disease
Varshini V. Suresh, Sathish Sivaprakasam, Yangzom D. Bhutia, et al.
Biomolecules (2025) Vol. 15, Iss. 4, pp. 580-580
Open Access
Page 1 - Next Page

Scroll to top